Sugi Predict

Sugi Predict / Compounds / SCHEMBL3077045

SCHEMBL3077045

SCHEMBL3077045

COc1ccc(-c2ccc(N)cc2)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.62
▸ MKNK2 Q9HBH9 1/20 0.62
▸ CYP2A6 P11509 2/20 0.56
▸ HSD17B1 P14061 1/20 0.56
▸ HSD17B2 P37059 1/20 0.56
▸ PIK3CA P42336 2/20 0.53
▸ PIK3CD O00329 1/20 0.53
▸ PIP5K1C O60331 1/20 0.53
▸ PIK3CB P42338 1/20 0.53
▸ PI4KA P42356 1/20 0.53
▸ PIK3CG P48736 1/20 0.53
▸ PI4KB Q9UBF8 1/20 0.53
▸ FYN P06241 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30578438 1.00 MKNK1 (0.62) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL3754419 0.87 CYP2A6 (0.68) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL31174412 0.87 CYP2A6 (0.68) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL9966497 0.84 MKNK1 (0.57) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL29536663 0.83 — —
SCHEMBL113293 0.83 — —
SCHEMBL16835945 0.82 MKNK1 (0.51) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL1422182 0.82 HSD17B1 (0.67) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL1422493 0.82 MKNK1 (0.59) MKNK1MKNK2CYP2A6HSD17B1HSD17B2
SCHEMBL12497850 0.82 MKNK1 (0.59) MKNK1MKNK2CYP2A6HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 — — EP disclosed
US-20230365559-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER AUCKLAND UNISERVICES LIMITED (NZ) 2023-11-16 — — US disclosed
EP-4217357-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER Auckland Uniservices Limited (NZ) 2023-08-02 — — EP disclosed
WO-2022064430-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER AUCKLAND UNISERVICES LIMITED (NZ) 2022-03-31 — — WO disclosed
EP-3915990-A1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER Centre National de la Recherche Scientifique (FR) 2021-12-01 — — EP disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 — — US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 — — US disclosed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 — — US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 — — EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 — — WO disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 — — WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MKNK1 51/4885MKNK2 48/4885CYP2A6 4092/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK MKNK1 51/4885MKNK2 48/4885CYP2A6 4092/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 MKNK1 67/4885MKNK2 51/4885CYP2A6 4826/4885
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER MKNK1 450/4885MKNK2 366/4885CYP2A6 4229/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MKNK1 44/4885MKNK2 48/4885CYP2A6 4043/4885
US-20230365559-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER DCK, DTYMK, TYMP MKNK1 261/4885MKNK2 230/4885CYP2A6 2344/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MKNK1 44/4885MKNK2 48/4885CYP2A6 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.